All In Biotech

Free tool

FAERS Monitor: Oravig

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022404 or its brand name (Oravig, Miconazole). Reports on generic versions are filed under their own applications.

Reports

2,337

Serious

1,973

84% of reports

Hospitalization

1,051

Death reported

260

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug interaction238
  • drug ineffective133
  • international normalised ratio increased127
  • diarrhoea123
  • nausea106
  • off label use89
  • urinary tract infection87
  • dyspnoea84
  • rash81
  • fatigue76
  • pain74
  • pyrexia70
  • vomiting69
  • acute kidney injury68
  • malaise62

Reports by year received

View as table
YearReports
200435
200525
200631
200745
200841
200943
201067
2011119
2012157
201364
201460
201578
2016101
2017182
2018225
2019178
2020144
2021120
2022126
2023159
2024130
2025106
2026100

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,822 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
international normalised ratio increasedSignal12740.334.04,808
drug interactionSignal23813.512.02,764
urinary tract infectionSignal874.63.7243
acute kidney injurySignal684.03.2151
pyrexia701.81.426
diarrhoea1231.71.437
rash811.71.422
dyspnoea841.31.17
vomiting691.31.05
malaise621.31.03
nausea1061.21.04
pain741.10.90
off label use890.90.71
drug ineffective1330.90.81
fatigue760.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.